C ardiovascular diseases (CVDs) are a leading cause of death in the world and a major barrier to sustainable human development (1).
In 2011, the United Nations formally recognized noncommunicable diseases, including CVDs, as a major concern for global health and set out an ambitious plan to dramatically reduce the effect of these diseases in all regions (2) . An increased awareness of these global noncommunicable disease goals has expanded attempts to track and benchmark national efforts at reducing CVD and other noncommunicable diseases (3, 4) .
The third Sustainable Development Goal recognized the importance of CVD by targeting a one-third reduction in premature mortality due to noncommunicable diseases (5) . Countries that take the SDG goals seriously will have to contend with a wide range of barriers limiting their ability to improve health care and reduce CVD risks. In many regions of the world, the relative position of CVD as a health problem remains unclear or is based on limited data.
Many low-and middle-income countries have implemented health examination surveys that have improved measurement of CVD and its associated risk factors (6) .
Systematic evaluation of data collected in death certificates, verbal autopsy, health surveys, prospective cohort studies, health system administrative data, and disease registries is needed to appropriately guide efforts to reduce the health burden of CVD. The GBD (Global Burden of Disease) study is an effort to continuously improve our understanding of the burden of diseases by integrating the available data on disease incidence, prevalence, and mortality to produce consistent, transparent, and up-to-date global, regional, and national estimates (7) .
The global number of CVD deaths and regional patterns of total CVD mortality were previously reported from the GBD 2013 study (8) vital registration. Models of disease incidence and prevalence now uniformly include estimates of excess mortality and, for stroke, cause-specific mortality, so that they are better informed by the available mortality data. For each incidence or prevalence data point, we matched the age-sex-location-year-causespecific mortality rate to produce a ratio conceptually equivalent to an excess mortality rate. Because of implausibly rapid increases in deaths reported due to atrial fibrillation, we have developed a unified model of atrial fibrillation that makes use of prevalence, case fatality, and mortality data to estimate both the nonfatal and fatal burden due to this condition.
DEFINING DISEASE CATEGORIES. CVD was estimated overall and separately for the 10 most common global causes of CVD-related death. These causes were ischemic heart disease (IHD), ischemic stroke, hemorrhagic and other stroke, atrial fibrillation, peripheral arterial disease (PAD), aortic aneurysm, cardiomyopathy and myocarditis, hypertensive heart disease, endocarditis, rheumatic heart disease (RHD), and a category for other CVD conditions. The GBD cause list is a hierarchical, mutually-exclusive, and collectively exhaustive list of causes of death. The 3 level 1 GBD causes consist of communicable, maternal, neonatal, and nutritional disorders; noncommunicable diseases; and injuries. Level 2 causes consist of 21 cause groups, such as neoplasms and CVD. Levels 3 and 4 consist of disaggregated subcauses (Online Methods Appendix Table 1 ).
Cause of death was defined by international standards governing the reporting of death certificates, in which a single underlying cause is assigned by a physician. For example, IHD was defined as an underlying cause of death across International Classification of Diseases (ICD) revisions (most recently ICD-10 I20 to I25, ICD-9 410 to 414) (12) . The leading causes included as "other cardiovascular and circulatory diseases" were nonrheumatic valvular disorders and pulmonary embolism. A proportion of deaths that were assigned on death certificates to nonfatal, undefined, or intermediate causes (e.g., cardiac arrest, heart failure, or hypertension) were redistributed using statistical regression methods or fixed proportions (9) . Redistribution of deaths coded to heart failure was accomplished using a regression model that accounted for the variable use of these codes by age, sex, and location. This approach improves upon methods that either exclude deaths coded to an intermediate cause or reassign them using a fixed proportion that ignores variation by age, sex, or location. Deaths due to unspecified types of stroke (ICD-10 I64) were distributed using the ratio of ischemic to hemorrhagic stroke deaths in a country's region or, for South Asia, the global ratio, stratified by age. A Bayesian noise reduction algorithm was applied to death data to improve estimation of the underlying mortality rate (see the Online Appendix for details). This noise reduction algorithm was adopted to improve upon prior methods in which 0 counts were excluded, an approach that leads to an upward bias in estimates. Verbal autopsy, a method in which a standardized interview collects information from household members on symptoms preceding death, was included as a data input only for total CVD, ischemic heart disease, and stroke deaths, and was excluded for other CVD causes of death.
Disease prevalence was estimated at a more granular level of specific disease sequelae, using input data from systematic reviews of the published scientific which accounts for out-of-hospital sudden cardiac death (13, 14) . Adjustments were made for the advent of troponin-testing technology for diagnosis of acute coronary syndromes during the years covered by the study using meta-analysis of its increased sensitivity (compared with prior markers) to adjust pre-2000 incidence rates upward by 56%. Stable angina was defined according to the Rose Angina Questionnaire, which was adjusted to account for the observed differences in survey and administrative data found in the United States. Cerebrovascular disease relied on a case definition developed by the World Health Organization and was estimated separately for 2 subcategories: 1) ischemic stroke; and 2) hemorrhagic or other nonischemic stroke (15) . Stroke data was adjusted to match our case definition of subtypespecific first-ever incident events, and was used to separately estimate acute and chronic stroke. PAD was defined by an ankle brachial index (ABI) <0.9, and symptomatic PAD was defined as self-report of claudicatory symptoms among those with ABI <0.9 (16).
Atrial fibrillation was defined by electrocardiogram and included atrial flutter. The prevalence of symptomatic heart failure was estimated using both health system administrative and population-based registry data, and was then attributed to specific underlying heart failure etiologies (some of which were not CVD).
Hypertensive heart disease was defined as symptomatic heart failure due to the direct and long-term effects of hypertension, with its nonfatal burden derived from the model of heart failure. Cardiomyopathy was defined as symptomatic heart failure due to primary myocardial disease or toxic exposures, such as alcohol, with its nonfatal burden derived from the model of heart failure (17) . Acute myocarditis was estimated as an acute and time-limited condition due to myocardial inflammation using health system administrative data. Endocarditis and RHD were defined by their clinical diagnosis. Estimates of RHD include cases identified by clinical history and physical examination, including auscultation or standard echocardiographic criteria for definite disease.
DATA SOURCES AND ANALYTIC METHODS.
A map of data availability for each country are included in Online Figures 1A and 1B (9) . The GBD 2015 study used country-level surveillance data, verbal autopsy, vital registration, published and unpublished disease registries, and published scientific reports. Table 1 summarizes data sources used to estimate CVD burden. Table 1 also shows the data representativeness index for nonfatal estimates, which is the proportion of age-sex-location strata with available data for nonfatal modeling shown by cause and over time. Tables 2 and 3 are tables of all data sources. Data sources for models are also available online from the Global Health Data Exchange (18). National income, metabolic and nutritional risk factors, and other country-level covariates were estimated from surveys and published systematic reviews. Analysis of mortality used Cause of Death Ensemble modeling (CODEm), an approach that incorporates country-level covariates, including agesex-country-year-specific estimates of CVD risk factors, national income, and other causal factors (Online Appendix). CODEm borrows strength across space, time, and age groups using a variety of geospatial model types, and weighs the results using tests of out-of-sample predictive validity. Analysis of disease prevalence used epidemiological state-transition-based disease modeling software, DisMod-MR, which accounts for study-level differences in measurement method (9). Disease-specific incidence, prevalence, case fatality, and mortality rates were (10, 11) . Briefly, disability weights were developed using household surveys in multiple countries that asked members of the general public to choose between lay descriptions of health states (20, 21) . Adjustment was made for comorbidity by simulating 40,000 individuals in each age-sexcountry-year stratum exposed to the independent probability of acquiring each condition based on disease prevalence.
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The 95% UIs reported for each estimate used 1,000
samples from the posterior distribution from the respective step in the modeling process, reported as the 2.5th and 97.5th values of the distribution. Age standardization was via the direct method, applying a global age structure. Least squares regression of death rates on SDI was used with a smoothing spline and dummy variables for outlier regions that skewed fit to capture the average relationship for each age-sex-cause group.
RESULTS
All results of the GBD 2015 study, including prevalence, mortality, YLL, YLD, and DALYs, for all country-years are available for download from the The relationship between SDI and the agestandardized CVD death rate at the global level is shown in Figure 3 . As SDI increases beyond 0.25, the highest CVD mortality rates shift from women to men. Relationship between age-standardized mortality rate for CVD and SDI over time. Each colored line represents a time trend of the relationship for the specified region.
Each point represents a specific year for that region. The black line represents the overall global trend for age-standardized death rate of CVD in relation to SDI.
CVD ¼ cardiovascular diseases; GBD ¼ Global Burden of Disease; SDI ¼ sociodemographic index.
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40 years of age, and the prevalence rose steeply with older age categories (Online Figure 4A ). (Figure 4) .
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This figure displays the relative distribution of age-standardized prevalence by CVD cause for 21 GBD world regions. Abbreviations as in years, increasing from an estimated 33 deaths per 100,000 (95% UI: 32 to 35 per 100,000) for those 40 to 44 years of age to 1,050 per 100,000 (95% UI: 1,025 to 1,076 per 100,000) by ages 75 to 79 years (Online Figure 4B ). Above 80 years of age, the IHD death rate was estimated to be more than twice that rate (2,671 per 100,000; 95% UI: 2,600 to 2,738 per 100,000) and was by far the leading global cause of death.
The estimated age-standardized IHD death rate was highest in Central Asia (336 per 100,000; 95% UI: 326 to 347 per 100,000) and Eastern Europe (326 per 100,000; 95% UI: 319 to 333 per 100,000), followed by Oceania, South Asia, and the Middle East/North Africa ( Table 3 ). These regions, as well as high-income North America and Latin America, had particularly high proportions of total CVD deaths that were due to IHD The prevalence of stroke began increasing above 40 years of age, reaching the highest rate for any 5-year age group for those 74 to 79 years of age (4, 201 cases per 100,000; 95% UI: 4,140 to 4,258 per 100,000), with the rate declining by one-half this amount among those over 80 years of age.
Oceania was the region with the highest prevalence of stroke (1,003 per 100,000; 95% UI: 985 to 1,025 per 100,000), followed by Eastern Europe, Central Asia, and Southeast Asia. The lowest stroke prevalence in the world, less than one-fifth that of the highest regions, was in Central Latin America (177 per 100,000; 95% UI: 174 to 180 per 100,000). The estimated agestandardized prevalence of ischemic stroke was greater than that of hemorrhagic stroke in most regions, but was the same for Andean Latin America.
There were 6.33 million deaths due to stroke in 2015 (95% UI: 6.18 to 6.49 million deaths), with 57% of these stroke deaths due to ischemic stroke. The stroke mortality rate began rising above 50 years of age, increasing for each older age group until it reached 1,812 per 100,000 (95% UI: 1,764 to 1,864 per 100,000) among those over age 80 years.
The estimated stroke age-standardized mortality rate in 2015 was also greatest in Oceania (191 per 100,000; 95% UI: 148 to 248 per 100,000), followed by 1,248 to 1,502 per 100,000) for those >80 years of age.
The prevalence was highest in Western sub-Saharan Africa, followed by Central and Eastern sub-Saharan Africa, tropical Latin America, and the Caribbean.
The lowest rates were estimated for Western and Eastern Europe.
There were 962,400 deaths (95% UI: 873,600 to 1,024,500 deaths) due to hypertensive heart disease in 2015. The mortality rate rose for ages >60 years, peaking at 296 per 100,000 (95% UI: 257 to 315 per 100,000) for age >80 years. Death rates due to hypertensive heart disease followed a similar pattern as the condition's prevalence. rate due to aortic aneurysm rose most quickly after 60 years of age, reaching a peak of 50 per 100,000 (95% UI: 48 to 53 per 100,000) above 80 years of age.
Tropical Latin America had the highest death rate due to aortic aneurysm, followed by Southern Latin America, high-income Asia Pacific, Australasia, and Oceania. Death rates due to aortic aneurysm were lowest in Western sub-Saharan Africa and East Asia. This death rate was almost 5Â higher, 116 per 100,000 (95% UI: 90 to 145 per 100,000) above 80 years of age than below that age. Atrial fibrillation mortality rates There were an estimated 115,700 prevalent cases of endocarditis in 2015 (95% UI: 108,000 to 125,000 cases). There was an increase and then decline in the mortality rate among children, which peaked among children 28 days to 1 year of age (0.22 cases per 100,000; 95% UI: 0.18 to 0.26 per 100,000). The prevalence rose quickly above 60 years of age, reaching 28 per 100,000 (95% UI: 24 to 34 per 100,000) above 80 years of age. The highest prevalence of endocarditis was estimated for Oceania, 14
per 100,000 (95% UI: 13 to 15 per 100,000), which was twice the rate of the next-highest region, Southern Latin America. The lowest rates were estimated for East Asia and Andean Latin America.
There were 84,900 deaths due to endocarditis in 2015. Mortality rates were highest at the extremes of the age range: 7 per 100,000 (95% UI: 4 to 9 per 100,000) among those in the first week of life; 8 per 100,000 (95% UI: 7 to 9 per 100,000) among those 75 to 79 years of age; and 22 per 100,000 (95% UI 21 to 24 per 100,000) older than 80 years of age.
Age-standardized mortality rates were greatest in Oceania, 6 per 100,000 (95% UI: 4 to 8 per 100,000), more than twice that of the next 2 regions, Central sub-Saharan Africa and Middle East/North Africa.
P e r i p h e r a l a r t e r i a l d i s e a s e . PAD was among the lowest-ranked CVD cause of DALYs in most world regions, but accounted for the largest proportion of cases of prevalent CVD in most world regions, reflecting high estimates of prevalence (based on surveys using ABI) and low estimates of symptomatic PAD (based on self-reported claudication among Ischemic heart disease Cardiomyopathy and myocarditis Endocarditis 0% C e n t r a l A s ia E a s t e r n E u r o p e C e n t r a l E u r o p e W e s t e r n E u r o p e
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This figure displays the relative distribution of age-standardized prevalence by CVD cause for 21 GBD world regions. Abbreviations as in highest above 80 years of age (24 per 100,000; 95% UI: 22 to 26 per 100,000). The Southern subSaharan region had the greatest age-standardized mortality rate, 3 per 100,000 (95% UI: 2 to 3 per 100,000), followed by Australasia, Eastern Europe, and the Caribbean, whereas the lowest mortality rates were estimated for Western sub-Saharan Africa, Andean Latin America, and Southeast Asia. It is notable that very high age-standardized death rates due to CVD were not limited to any single region of the world, occurring among a subset of countries throughout Eastern Europe, Central Asia, the Middle East, South America, sub-Saharan Africa, and Oceania. There were also extremely large differences in estimated country-level age-standardized prevalence of CVD, ranging from <4,000 to >11,000 prevalent cases per 100,000 persons in 2015. PERIPHERAL ARTERIAL DISEASE. We estimated that PAD is the most prevalent cardiovascular condition globally, although low estimated rates of claudication and mortality made it a minor contributor to DALYs.
The high prevalence of PAD in comparison to IHD is a notable finding that may reflect the ease of its diagnosis using ABI, compared with more complex diagnostic testing required for IHD. Further attention should be paid to the use of ABI or palpation of foot pulses as a screening tool for overall vascular risk in low-income settings (41, 42) . There is some evidence that even those with asymptomatic PAD would benefit significantly from inexpensive medications, such as an angiotensin-converting enzyme inhibitor or antiplatelet agents (43, 44) . The GBD study has reported subnational estimates for a growing number of countries; however, the current report is limited to country-level estimates (50) (51) (52) . There is substantial small-area variation in CVD burden within countries, and our national estimates represent only an average level for an entire country. Even these national estimates are important starting points for improving evidence available to policymakers.
The GBD study accounts for comorbidity using a simulation method that assumes an independent probability of having any disease state. A sensitivity analysis found that taking dependent and independent comorbidity into account changed overall estimated YLDs by a small amount that increased with age, ranging from 0.6% to 3.4%. Because CVD is more common at older ages, the assumption of independence may have a larger effect on this group of causes.
Unfortunately, data on the full correlation structure of prevalent CVD conditions remains limited. 
